The iRECIST guideline addresses the singularities of immunotherapies, ensuring consistent trial design and interpretation of tumour progression measurements for immune modulators. The guideline takes into account distinctive behaviours linked to these types of therapeutics, such as delayed responses after pseudoprogression, and describes a standard approach to solid tumour measurement and definitions for objective change in tumour size which can be used in immunotherapy clinical trials.